Murali Ramanathan PhD

Murali Ramanathan

Murali Ramanathan
PhD


Professional Summary:

My laboratory is involved in clinical and translational research program in multiple sclerosis (MS) therapeutics.

My laboratory has investigated the neuroimmunological and genomic mechanisms that contribute to the heterogeneity of clinical treatment responses for this chronic, disabling neurological disease. Currently, the broad focus of my MS research is to delineate the interactions among patient-specific, environmental and genetic factors that contribute to inter-individual differences in disease progression.

We employ a unique multi-disciplinary approach to research by leveraging our strengths in pharmaceutical sciences and bioengineering and also through my productive collaborations with scientists from clinical disciplines such as neurologists, neuroradiologists, neuropsychologists and also from quantitative disciplines such computer science and biostatistics. Through these collaborations, our group has been able take on challenging scientific problems that could not be undertaken by any one of us individually.

My multi-disciplinary research spans two inter-related areas: i) clinical research on the roles of environmental factors in MS progression and, ii) molecular and quantitative clinical pharmacology, particularly machine learning and artificial intelligence techniques for pharmacometrics and quantitative systems pharmacology.

My recent work has focused on cholesterol and lipid biomarkers in multiple sclerosis disease progression. My group has investigated other compelling environmental factors in MS including immune responses to Epstein-Barr virus exposure, vitamin D metabolism and smoking. I have the necessary expertise and record in quantitating environmental factors and surrogate markers in MS.

We also have extensive experience in pharmaceutical applications of "big data" and modeling analyses using machine learning and artificial intelligence techniques of large high-dimensional data sets containing environmental factors, genetic and immunological biomarkers, quantitative neuroimaging metrics and clinical measures in MS.


If you wish to support Dr. Ramanathan‘s multiple sclerosis research with a contribution, please visit his research giving form

Education and Training:

  • PhD, Bioengineering, University of California, San Francisco (1994)
  • MS, Chemical Engineering, Iowa State University (1989)
  • B. Tech., Indian Institute of Technology (1983)

Awards and Honors:

  • Stephen H. Kelley Award, Western New York Chapter, National Multiple Sclerosis Society (2013)
  • Second place, Western New York Inventor of the Year, Physical Sciences, Niagara Frontier Intellectual Property Law Association (2011)
  • Visionary Award, Enzee Universe (2011)
  • Teacher of the Year Nominee (2010)
  • Faculty of 1000 (2008)
  • The Whitaker Prize (2005)
  • Best Applications Paper Runner up Award (2004)
  • Best Applications Paper Runner up Award: The Association for Computing Machinery (ACM) Special Interest Group in Knowledge Discovery and Data Mining (SIGKDD 2004) (2004)
  • Teacher of the Year (2002)
  • Innovations in Teaching (1997)
  • Golden Key Honor Society (1996)
  • Regents Fellowship (1991)
  • Regents Fellowship (1990)
  • Regents Fellowship (1989)
  • Premium for Academic Excellence (1989)
  • Premium for Academic Excellence (1988)
  • Premium for Academic Excellence (1987)
  • B.C. Roy Gold Medal and Institute Silver Medal (1983)
  • P.C. Ray Award of the Indian Institute of Chemical Engineers (1983)

Research Expertise:

  • : Treatment of multiple sclerosis (MS), an inflammatory-demyelinating disease of the central nervous system that affects over 1 million patients worldwide
  • : Molecular mechanisms of disease and treatment effects in MS and other demyelinating diseases
  • : Genomics of non-responsiveness and Therapy optimization
  • : Gene expression profiling and proteomics
  • : Mathematical models for pharmacogenomics, signal transduction processes and immunomodulatory protein networks
  • Machine learning/artificial intelligence for pharmacometrics and quantitative systems pharmacology.: Machine learning/artificial intelligence for pharmacometrics and quantitative systems pharmacology.

Patents:

  • Bridging centrality: a concept and formula to identify bridging nodes in sc Docket Number: 6089 Type: Regular (2007)
  • High Throughput Spectrofluormetric Screen for Drug Binding to Human Serum P Type: Regular (2001)


Professional Memberships:

  • American Academy of Neurology (2007)
  • Cooperative Research Project on “Antisense Diagnosis and Therapy”; Member, Cooperative Research Project on “Antisense Diagnosis and Therapy” between Kanazawa Univ., Japan, Sheffield Univ., United Kingdom, and the University at Buffalo (1996–1999)
  • Golden Key Honor Society; Honorary Membership (1996–present)
  • American Association for the Advancement of Science (1995)
  • American Association of Pharmaceutical Scientists (1995)

Presentations:

  • "Does first year MRI and clinical activity correlate with long term clinical response to glatiramer acetate in multiple sclerosis patients" American Academy of Neurology; American Academy of Neurology (2013)
  • "Does first year MRI and clinical activity correlate with long term clinical response to glatiramer acetate in multiple sclerosis patients" American Academy of Neurology; American Academy of Neurology (2013)
  • "Anti-phospholipid antibodies are associated with response to interferon-á-1a treatment: Results from a 3-year longitudinal study" 28th Congress of ECTRIMS; ECTRIMS (2012)
  • "Cholesterol affects retinal nerve fiber layer thickness in MS patients with optic neuritis" 28th Congress of ECTRIMS; ECTRIMS (2012)
  • "Clinical characterisation of interferon-inhibitory activity in multiple sclerosis patients treated with interferon-á-1a" 28th Congress of ECTRIMS; ECTRIMS (2012)
  • "Conventional and non-conventional MRI characteristics of familial and sporadic MS patients" 28th Congress of ECTRIMS; ECTRIMS (2012)
  • "Heart disease, overweight and cigarette smoking are associated with increased prevalence of extra-cranial venous abnormalities" 28th Congress of ECTRIMS; ECTRIMS (2012)
  • "MicroRNA and Dicer expression as a marker of MS dysimmunity and response to interferon therapy" 28th Congress of ECTRIMS; ECTIMS (2012)
  • "Prevalence, sensitivity and specificity of chronic cerebrospinal insufficiency in other neurological diseases. A case-control study" 28th Congress of ECTRIMS; ECTRIMS (2012)
  • 5th Joint Triennial Congress of ECTRIMS/ACTRIMS; ECTRIMS (2011)
  • "Alcohol consumption patterns and clinical/MRI measures in multiple sclerosis" 5th Joint Triennial Congress of ECTRIMS/ACTRIMS (2011)
  • "Inter-dependence of vitamin D levels with serum lipid profiles in multiple sclerosis" 5th Joint Triennial Congress of ECTRIMS/ACTRIMS; ECTIMS (2011)
  • "Differences in genetic architecture between subjects with pediatric- and adult-onset multiple sclerosis" AAN Annual Meeting; American Academy of Neurology (2011)
  • "HLA DRB1*1501 positivity is associated with increased inflammatory activity and lesion burden at the first demyelinating event" AAN Annual Meeting; American Academy of Neurology (2011)
  • "Increased familial autoimmune prevalence in pediatric multiple sclerosis and monophasic demyelinating disorders" AAN Annual Meeting; American Academy of Neurology (2011)
  • "Obesity as a risk factor in pediatic demyelinating disorders" AAN Annual Meeting; American Academy of Neurology (2011)
  • "Optical coherence tomography as a visual outcome measure in children with demyelinating diseases" AAN Annual Meeting; American Academy of Neurology (2011)
  • "Serum cholesterol profiles adversely affect clinical and MRI outcomes in multiple sclerosis" AAN Annual Meeting; American Academy of Neurology (2011)
  • "Vagal nerve stimulation and the immune modulation in patients with refractory epilepsy" AAN Annual Meeting; American Academy of Neurology (2011)
  • "Associations of chronic venous insufficiency with HLA DRB1*1501 status in multiple sclerosis" ECTRIMS; ECTRIMS (2010)
  • "Associations of serum cholesterol with clinical outcomes in multiple sclerosis" ECTRIMS; ECTRIMS (2010)
  • "Clinical correlates of chronic cerebrospinal venous insufficiency in multiple sclerosis" ECTRIMS; ECTRIMS (2010)
  • "MRI results of blinded chronic cerebrospinal venous insufficiency study in patients with multiple sclerosis, healthy controls and patients with other neurologic diseases" ECTRIMS; ECTRIMS (2010)
  • "Combined Transcranial and Extracranial Venous Doppler Evaluation (CTEVD) Study: Description of design and interim results of an epidemiological study of the prevalence of chronic cerebrospinal insufficiency in MS and related diseases." American Academy of Neurology (2010)
  • "Lower risk for developing neutralizing antibodies to interferon in children with MS on interferon treatment" American Academy of Neurology (2010)
  • "Phytosterols ameliorate clinical manifestations and inflammation in Experimental Autoimmune Encphaomyelitis" Experimental Biology; FASEB (2010)
  • "Vitamin D and cognitive impairment in multiple sclerosis (MS)" American Academy of Neurology (2010)
  • "Vitamin D metabolites are linked to clinical and MRI outcomes in multiple sclerosis patients" American Academy of Neurology (2010)
  • "Examining the association between high-density lipoprotein levels and disability in patients with multiple sclerosis" American Academy of Neurology (2009)
  • "Serum vitamin D levels are associated with multiple sclerosis disease severity" American Academy of Neurology (2009)
  • "Visual motor and perceptual abnormalities in children with demyelinating disorders" American Academy of Neurology (2009)
  • "Multi-Agent Model Analysis of the Containment Strategy for Avian Influenza (AI) in South Korea" 2008 IEEE International Conference on Bioinformatics and Biomedicine; IEEE (2008)
  • "Does multiple sclerosis become an ischemic disease over time? A 3-year follow-up study of patients positive for the presence of anti-phospholipid antibodies" ACTRIMS-ECTRIMS-LACTRIMS (2008)
  • "Epstein-Barr virus is associated with gray matter atrophy and lesion injury in multiple sclerosis" ACTRIMS-ECTRIMS-LACTRIMS (2008)
  • "HLA B7/A2, Epstein-Barr Virus antibodies and magnetic resonance imaging in multiple sclerosis: a case for gene-environment interactions" ACTRIMS-ECTRIMS-LACTRIMS (2008)
  • "Natalizumab use in a large multiple sclerosis center: ascertaining the therapeutic benefit and the causes for treatment discontinuation" ACTRIMS-ECTRIMS-LACTRIMS; UB (2008)
  • "Retinal nerve fiber thickness in inflammatory demyelinating diseases of childhood onset" ACTRIMS-ECTRIMS-LACTRIMS (2008)
  • "Bridging Centrality: Graph Mining from Element Level to Group Level" the 14th ACM SIGKDD International Conference on Knowledge Discovery & Data Mining; ACM (2008)
  • "Information Theoretic Methods for Detecting Multiple Loci Associated with Complex Diseases" 8th International Workshop on Data Mining in Bioinformatics (BIOKDD08); ACM (2008)
  • "Comarison of the immunomodulatory effects of the plant sterol B-sitosterol to simvastatin in prepheral blood cells from multiple sclerosis patients" American Academy of Neurology (2008)
  • "Genomic Effects of Interferon- Treatment After the First Dose and on Chronic Dosing: Relationships to 5-Year Clinical Outcomes in Multiple Sclerosis Patients" American Academy of Neurology (2008)
  • "Gray matter atrophy and destructive T1 lesions are more frequent in familial cases with multiple sclerosis and especially in those with first degree relatives" American Academy of Neurology (2008)
  • "Gray matter atrophy and higher lesion volumes differentiate patients with primary anti-phospholipid syndrome and multiple sclerosis" American Academy of Neurology (2008)
  • "Multiple sclerosis patients with presence of anti-phospholipid antibodies develop more severe brain damage over 3 years" American Academy of Neurology (2008)
  • "Premorbid neurological and neurocognitive impairment is predominant in younger children with acquired demyelinating disorders" American Academy of Neurology (2008)
  • "The rs2030324 SNP of brain derived neurotrophic factor (BDNF) is associated with memory in multiple sclerosis" American Academy of Neurology (2008)
  • "Information Theoretic Metrics for Visualizing Gene Environment Interactions" American Society of Human Genetics Annual Meeting 2007; American Society of Human Genetics (2007)
See all (37 more)

Service Activities:

  • Pharmacy Practice Faculty Search Faculty search for Patricia Grace position Interviewed and identified faculty member; Member (2013)
  • Faculty Search Committee Search for inter-disciplinary CDESE faculty member Conducted search, interviews; Other (2013)
  • Graduate Admission Committee Oversee admission BS/MS, MS and Ph.D. programs Oversee admissions.; Other (2008)
  • Graduate Studies Committee Oversee BS/MS, MS and Ph.D. programs Oversee curriculum, student advising; Other (2008)
  • Director of Graduate Studies Oversee BS/MS, MS and Ph.D. programs Streamlined Graduate Admissions and created new processes.; Other (2008)
  • Associate Editor The AAPS Journal To serve as Associate Editor I have been actively involved in organizing theme issues.; Other (2008)
  • Faculty of 1000 Biology F1000 Biology I am Faculty in Faculty of 1000 Biology for Pharmacokinetics and Drug Delivery. This is an international group of experts that reviews the literature and highlights the most interesting papers.; Other (2008)
  • Biomedical Engineering Design Team To design the Biomedical Engineering Department The committee was instrumental in developing the program.; Member (2007)
  • University Computer Standards Committee To review standards for computers and software for students; Member (2007)
  • Pharmacy Applicants Interview Panel Interview applicants; Member (2007)
  • Health Sciences Divisional Committee; Member (2006)
  • Phi Delta Chi Serve as faculty advisor for this pharmacy fraternity. The fraternity has grown considerably and conducts numerous fundraising and health care events in the community; Other (2006)
  • Pharmacy Admissions Review Panel Review applicants for the Pharm.D. program The committee has done an outstanding job of reviewing the large number of applicants to the program.; Reviewer (2005)
  • Department of Pharmaceutical Sciences Bioinformatics Search Committee (2003–present)
  • Department of Pharmaceutical Sciences Graduate Affairs Committee (2003–present)
  • Health Sciences Divisional Committee (2003–present)
  • School of Pharmacy Admissions Committee (2003–present)
  • University Search Committee for Bioinformatics Center of Excellence (2003–present)

School News:

In the Media:


Clinical Specialties:

Clinical Offices:

Insurance Accepted:



Contact Information

355 Pharmacy Building
Buffalo, New York 14214-8033
Phone: (716) 645-4846
murali@buffalo.edu